Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.39 |
| ▸ | PPARG | P37231 | 7/20 | 0.39 |
| ▸ | PPARD | Q03181 | 7/20 | 0.39 |
| ▸ | PPARA | Q07869 | 7/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 5/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.39 |
| ▸ | FABP4 | P15090 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TLR2 | O60603 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3361822 | 0.78 | AKR1B1 (0.46) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL3361824 | 0.78 | AKR1B1 (0.46) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL11850685 | 0.76 | GPR84 (0.48) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL3363214 | 0.76 | GPR84 (0.48) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL11849168 | 0.76 | GPR84 (0.48) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL25425408 | 0.76 | GPR84 (0.48) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL870550 | 0.76 | GPR84 (0.48) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL11849165 | 0.76 | GPR84 (0.48) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL9997344 | 0.76 | GPR84 (0.48) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL11850680 | 0.76 | GPR84 (0.48) | AKR1B1GPR84PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101702-B2 | Fermentative preparation process for and crystal forms of cytostatics | NOVARTIS AG (CH) | 2006-09-05 | — | — | US | claimed |
| CN-1229502-C | Fermentation preparation method of cell inhibitor and crystal form thereof | NOVARTIS AG (CH) | 2005-11-30 | — | — | CN | claimed |
| EP-1054994-B1 | FERMENTATIVE PREPARATION PROCESS FOR CYTOSTATICS AND CRYSTAL FORMS THEREOF | NOVARTIS AG (CH) | 2004-11-17 | — | — | EP | claimed |
| US-20040142990-A1 | Fermentative preparation process for and crystal forms of cytostatics | HOFMANN HANS (CH) | 2004-07-22 | — | — | US | claimed |
| US-20030220379-A1 | Fermentative preparation process for and crystal forms of cytostatics | HOFMANN HANS (CH) | 2003-11-27 | — | — | US | claimed |
| US-20030194787-A1 | Concentrating epothilones in culture media; using a cyclodextrin or derivative complexing agent; reverse phase chromatography with acetonitrile as eluant; Sorangium cellulosum obtained by mutagenesis | HOFMANN HANS (CH) | 2003-10-16 | — | — | US | claimed |
| US-20020165256-A1 | Fermentative preparation process for and crystal forms of cytostatics | HOFMANN HANS (CH) | 2002-11-07 | — | — | US | claimed |
| CN-1291239-A | Fermentation preparation method of cell inhibitor and crystal form thereof | NOVARTIS AG (CH) | 2001-04-11 | — | — | CN | claimed |
| US-6194181-B1 | PRODUCING EPOTHIOLONES IN A CULTURE MEDIUM BY PROVIDING MICROORGANISMS SUCH AS MYXOBACTERIA WHICH PRODUCE EPOTHIOLONES, AND ADDING A COMPLEX-FORMING AGENT SOLUBLE IN THE CULTURE MEDIUM, SUCH AS CYCLODEXTRINS; ANTITUMOR AGENTS | NOVARTIS AG (CH) | 2001-02-27 | — | — | US | claimed |
| EP-1054994-A2 | FERMENTATIVE PREPARATION PROCESS FOR CYTOSTATICS AND CRYSTAL FORMS THEREOF | Novartis AG (CH) | 2000-11-29 | — | — | EP | claimed |
| WO-1999042602-A2 | FERMENTATIVE PREPARATION PROCESS FOR CYTOSTATICS AND CRYSTAL FORMS THEREOF | NOVARTIS AG (CH) | 1999-08-26 | — | — | WO | claimed |
| US-20090326239-A1 | FERMENTATIVE PREPARATION PROCESS FOR AND CRYSTAL FORMS OF CYTOSTATICS | HOFMANN HANS | 2009-12-31 | — | — | US | disclosed |
| US-20070197611-A1 | Fermentative preparation process for and crystal forms of cytostatics | HOFMANN HANS | 2007-08-23 | — | — | US | disclosed |
| US-7101702-B2 | Fermentative preparation process for and crystal forms of cytostatics | NOVARTIS AG (CH) | 2006-09-05 | — | — | US | disclosed |
| CN-1229502-C | Fermentation preparation method of cell inhibitor and crystal form thereof | NOVARTIS AG (CH) | 2005-11-30 | — | — | CN | disclosed |
| US-6194181-B1 | PRODUCING EPOTHIOLONES IN A CULTURE MEDIUM BY PROVIDING MICROORGANISMS SUCH AS MYXOBACTERIA WHICH PRODUCE EPOTHIOLONES, AND ADDING A COMPLEX-FORMING AGENT SOLUBLE IN THE CULTURE MEDIUM, SUCH AS CYCLODEXTRINS; ANTITUMOR AGENTS | NOVARTIS AG (CH) | 2001-02-27 | — | — | US | disclosed |
| EP-1054994-A2 | FERMENTATIVE PREPARATION PROCESS FOR CYTOSTATICS AND CRYSTAL FORMS THEREOF | Novartis AG (CH) | 2000-11-29 | — | — | EP | disclosed |
| US-6121029-A | NUCLEOTIDE SEQUENCES ENCODING AT LEAST ONE POLYPEPTIDE FROM POLYKETIDE SYNTHASE; FOR RECOMBINANT PRODUCTION OF ANTICARCINOGENIC AGENTS | NOVARTIS AG (CH) | 2000-09-19 | — | — | US | disclosed |
| WO-1999066028-A2 | GENES FOR THE BIOSYNTHESIS OF EPOTHILONES | NOVARTIS AG (CH) | 1999-12-23 | — | — | WO | disclosed |
| WO-1999042602-A2 | FERMENTATIVE PREPARATION PROCESS FOR CYTOSTATICS AND CRYSTAL FORMS THEREOF | NOVARTIS AG (CH) | 1999-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142990-A1 | Fermentative preparation process for and crystal forms of cytostatics | TALDO1, PYCR1, THPO | AKR1B1 169/4885GPR84 4537/4885PPARG 4350/4885 |
| US-20030220379-A1 | Fermentative preparation process for and crystal forms of cytostatics | TALDO1, PYCR1, THPO | AKR1B1 169/4885GPR84 4537/4885PPARG 4350/4885 |
| US-20020165256-A1 | Fermentative preparation process for and crystal forms of cytostatics | TALDO1, PYCR1, THPO | AKR1B1 169/4885GPR84 4537/4885PPARG 4350/4885 |
| US-20070197611-A1 | Fermentative preparation process for and crystal forms of cytostatics | TALDO1, PYCR1, THPO | AKR1B1 168/4885GPR84 4537/4885PPARG 4382/4885 |
| US-20090326239-A1 | FERMENTATIVE PREPARATION PROCESS FOR AND CRYSTAL FORMS OF CYTOSTATICS | TALDO1, PYCR1, THPO | AKR1B1 169/4885GPR84 4537/4885PPARG 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.